This was the stock's third consecutive day of gains.

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...

Wellington motorists are being told to expect delays heading into the city this morning after a crash where two main ...

Williams County Public Library will hold a retirement reception in honor of Stryker Library Assistant Linda Woodall.

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...

As the solstice approaches, Gavin Haines recounts his state-altering night at the stones – and how to do it ...